Entopsis is a clinical-stage biotechnology company developing novel therapeutics for neurodegenerative diseases, with a primary focus on modulating the kynurenine pathway and targeting [alpha-synuclein](/proteins/alpha-synuclein) pathology. The company is headquartered in the United States and is advancing innovative approaches to address the underlying mechanisms of [Parkinson's disease](/diseases/parkinsons-disease) and other neurodegenerative disorders[@entopsis2024].
Company Information
| Attribute | Details | |-----------|---------| | Headquarters | United States | | Founded | 2012 | [@entopsis2024] | Focus | Kynurenine pathway modulators, alpha-synuclein | | Status | Clinical stage |
Technology Platform
Kynurenine Pathway Modulation
Entopsis's lead approach targets the kynurenine pathway, a major route of tryptophan metabolism in the immune system and brain. This pathway generates several neuroactive metabolites that can be:
Neurotoxic: Quinolinic acid and 3-hydroxykynurenine damage [neurons](/entities/neurons)
Neuroprotective: Kynurenic acid has neuroprotective properties
Therapeutic Approach:
Modulating the balance of kynurenine pathway metabolites
Reducing toxic metabolite production
Enhancing neuroprotective metabolite levels
Alpha-Synuclein Targeting
The company also develops therapies targeting alpha-synuclein aggregation, a key pathological feature of Parkinson's disease.
Pipeline
ENT-01 (Lead Program)
ENT-01 is Entopsis's lead clinical candidate.
...
Overview
Entopsis is a clinical-stage biotechnology company developing novel therapeutics for neurodegenerative diseases, with a primary focus on modulating the kynurenine pathway and targeting [alpha-synuclein](/proteins/alpha-synuclein) pathology. The company is headquartered in the United States and is advancing innovative approaches to address the underlying mechanisms of [Parkinson's disease](/diseases/parkinsons-disease) and other neurodegenerative disorders[@entopsis2024].
Company Information
| Attribute | Details | |-----------|---------| | Headquarters | United States | | Founded | 2012 | [@entopsis2024] | Focus | Kynurenine pathway modulators, alpha-synuclein | | Status | Clinical stage |
Technology Platform
Kynurenine Pathway Modulation
Entopsis's lead approach targets the kynurenine pathway, a major route of tryptophan metabolism in the immune system and brain. This pathway generates several neuroactive metabolites that can be:
Neurotoxic: Quinolinic acid and 3-hydroxykynurenine damage [neurons](/entities/neurons)
Neuroprotective: Kynurenic acid has neuroprotective properties
Therapeutic Approach:
Modulating the balance of kynurenine pathway metabolites
Reducing toxic metabolite production
Enhancing neuroprotective metabolite levels
Alpha-Synuclein Targeting
The company also develops therapies targeting alpha-synuclein aggregation, a key pathological feature of Parkinson's disease.
Pipeline
ENT-01 (Lead Program)
ENT-01 is Entopsis's lead clinical candidate.
| Property | Description | |----------|-------------| | Type | Small molecule | | Mechanism | Kynurenine pathway modulator | | Indication | Parkinson's Disease | | Phase | Phase 2 | | Status | Clinical development |
Development Highlights:
Orally bioavailable small molecule
Targets neuroinflammation via kynurenine pathway
Potential disease-modifying approach
Clinical Development:
Phase 1: Safety and tolerability in healthy volunteers
Phase 2: Exploring efficacy in Parkinson's disease patients